– USA, PA – Cognition Therapeutics, Inc., a clinical-stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage response pathways, today announced the election of Jack Khattar as chairman of the board of directors, replacing Bob Gailus, who has retired from the board of directors.
Mr. Khattar, the founder and CEO of Supernus Pharmaceuticals, was appointed in 2020 to serve as a member of the Cognition board of directors.
“Even in the short time that he has been a member of the board, Jack’s contributions have been significant. As chairman, we will draw more heavily on Jack’s expertise as we pursue a growing repertoire of indications and clinical plans,” said CEO, Lisa Ricciardi, “Bob’s retirement from the board comes after a remarkable tenure. He was one of Cognition’s earliest angel investors and continued to provide sage advice and support for more than a decade. We wish Bob well in his retirement.”
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. has discovered and is developing a pipeline of novel, disease-modifying, oral drug candidates to treat a broad array of neurodegenerative and neuro-ophthalmic disorders. Our pipeline compounds uniquely target the sigma-2 (σ-2) receptor, a key regulator of the cellular damage response. CT1812, our lead product candidate, is being assessed in a comprehensive clinical program for Alzheimer’s disease, including a 540-person Phase 2 study in collaboration with ACTC and supported by a competitive grant from the National Institute on Aging. Additional information about Cognition and its product candidates may be found online at www.cogrx.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.